Fresenius Medical Care surprisingly boosts profits - Fresenius Medical Care Surges Past 2025 Targets After Restructuring
Fresenius Medical Care (FMC), under the leadership of CEO Helen Giza, has successfully navigated a significant restructuring following profit warnings during the COVID-19 pandemic. The company has reaffirmed its annual targets for 2025 and reported surprisingly strong profit growth in the third quarter.
Despite sluggish growth in the U.S., FMC's largest marketplace, the company's revenue grew by 3% to just under €4.9 billion, exceeding forecasts. Adverse currency effects did impact performance, but net profit attributable to shareholders surged by nearly a third (29%) to €275 million, outperforming analyst expectations.
The restructuring, details of which are not publicly available, involved eliminating thousands of jobs, streamlining the organizational structure, optimizing workflows, logistics, and networks, and divesting unprofitable clinics and non-core assets. FMC, a leading provider of treatments for chronic kidney failure, maintains a global network of 3,628 dialysis clinics serving 293,620 patients as of the end of September.
Fresenius Medical Care, under Helen Giza's leadership, has shown resilience in the face of challenges, exceeding expectations in profit growth despite headwinds in its largest marketplace. The company's restructuring efforts, though specifics remain unclear, have contributed to this positive outcome. FMC continues to be a significant player in the global dialysis market.
Read also:
- India's Agriculture Minister Reviews Sector Progress Amid Heavy Rains, Crop Areas Up
- Over 1.7M in Baden-Württemberg at Poverty Risk, Emmendingen's Housing Crisis Urgent
- Life Expectancy Soars, But Youth Suicide and Substance Abuse Pose Concern
- Cyprus, Kuwait Strengthen Strategic Partnership with Upcoming Ministerial Meeting
